New Bayer site to make traditional Chinese and Western consumer health meds

Bayer snapped up China's Dihon in 2014 with the idea of combining Dihon's traditional Chinese medicines with Bayer's Western OTC products in a major consumer health play in the country. Now it has a large new plant there to produce both kinds of products. Last week, the drugmaker opened the first phase of a CNY 1.4 billion ($213 million), plant, which at 111,534 square meters (1,200,542 square feet) is Bayer's second largest OTC facility in the Asia Pacific. It will soon be producing Bayer's key TCM product, Dan E Fu Kang, which is marketed as a gynecological medicine for women's health indications including dysmenorrhea. More from FiercePharmaManufacturing | More

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.